Biotechnology
Samsung Biologics Reports First Quarter 2021 Financial Results
* Q1'21 revenue of KRW 260.8 billion increased 26% compared to Q1'20. * Q1'21 operating profit of KRW 74.3 billion increased 19% compared to Q1'20. * Q1'21 operating margin held steady at 28%. * All manufacturing facilities remain fully operational, without any disruptions caused by the COV...
2021-04-28 16:37
4489
TCI Co., Ltd. becomes Asia's first biotechnology company whose climate ambitions are validated by SBTi
TAIPEI, April 27, 2021 /PRNewswire/ -- TCI Co., Ltd. (8436. TWO), the leading nutraceutical ODM company, announced onApril 22nd that it is finally, after six months of review, recognized by the Science Based Targets Initiative (SBTi) as "committed" to aligning its actions to reduce greenhouse ...
2021-04-27 15:53
2080
PharmAbcine to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
DAEJEON, South Korea, April 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will present an e-poster featuring non-clinical data of PMC-403 at the Association for ...
2021-04-26 20:00
1593
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center...
2021-04-26 19:00
1814
Wuxi Strives to Build a World-class Biomedical Industry Chain
WUXI, China, April 22, 2021 /PRNewswire/ -- From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi,China. More than 160 experts including Hejie, Fan Chunhai and many other academicians carried out forward-looking, authoritative, and predictive exchanges and dialogue...
2021-04-22 19:06
1093
ATH434 protects brain cells and improves motor function in Parkinsonian disorder
MELBOURNE, Australia , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of...
2021-04-21 20:11
2435
Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research
LOS ANGELES, April 21, 2021 /PRNewswire/ -- Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor,The Craftory, alongside TechBio investor ARTIS Ven...
2021-04-21 20:00
2845
Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, "Driven. For Life."
INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the
world's leading contract development and manufacturing organization, celebrated
the 10th anniversary of its founding today at its global headquarters in
Songdo, Incheon via a virtual ceremony.
2021-04-21 19:00
1563
China Biologic Announces Completion of Going Private Transaction
BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger...
2021-04-21 04:30
4831
Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005
SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of i...
2021-04-20 20:54
1091
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration
SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolyti...
2021-04-20 08:30
1668
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform
LAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device ...
2021-04-20 05:00
2293
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...
2021-04-19 20:15
1614
Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy
SUZHOU, China, April 19, 2021 /PRNewswire/ -- On April 16, 2021, Suzhou Porton BiologicsLtd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO se...
2021-04-19 20:00
4506
PharmAbcine announces Clinical Trial Collaboration with MSD for the Phase II study in mTNBC
DAEJEON, South Korea, April 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has entered into an agreement with MSD to initiate a Phase II combination trial of olin...
2021-04-19 20:00
1503
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer
SUZHOU, China, April 18, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been success...
2021-04-19 08:00
1730
Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functio...
2021-04-16 08:00
1320
New Pathway Launched for Pioneering Life Science Companies Seeking Japanese Market Entry
TOKYO, April 15, 2021 /PRNewswire/ -- Today, pioneering life science organizations seeking to navigate Japanese market entry gained a new pathway. Shonan Health Innovation Park ("Shonan iPark", Kanagawa Prefecture,Japan) announced today new membership offerings for innovation and expansion-focuse...
2021-04-15 21:00
1365
Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
HANGZHOU, China, April 14, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the global phase III clinical trial (BURAN) at Shanghai Eastern Hospital Medical Center inChin...
2021-04-15 09:00
2354
Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing
SUZHOU, China, April 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, recently announced a strategic partnership with Hain...
2021-04-14 22:18
5594
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5201
